A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 27-40

  Evans, Marc ^a   Mcewan, Phil ^b   O'Shea, Richard ^c   George, Lindsay ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Clinical effectiveness; Costeffectiveness; Incretin therapies; Routine clinical practice; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RETROSPECTIVE STUDY; VOMITING; WEIGHT CHANGE;

EID: 84888630523     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0015-6     Document Type: Article

References (26)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-96.
2. Amori RE, Lau J, Pittas G. Efficacy and safety of incretin therapy in type 2 diabetes. JAMA. 2007; 298:194-206.
3. Victoza 6 mg/ml solution for injection in pre-filled pen (summary of product characteristics). Novo Nordisk Limited; 2012. http://www.medicines.org.uk/emc/medicine/21986/. Accessed 04 Oct 2012.
4. Byetta 5micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen (summary of product characteristics). Eli Lilly and Company Limited; 2012. http://www.medicines.org.uk/EMC/medicine/19257/ Accessed 04 Oct 2012.
5. BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection (summary of product characteristics). Eli Lilly and Company Limited; 2011. http://www.medicines.org.uk/EMC/medicine/24665/. Accessed 04 Oct 2012.
6. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh NR. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;5:CD006423.
7. Pratley RE, Nauck M, Bailey T, for the 1860- LIRA-DPP-4 Study Group, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447-56.
8. Pratley R, Nauck M, Bailey T, 1860-LIRA-DPP-4 Study Group, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397-407.
9. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-52.
10. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, doubleblind, crossover study. Diabetes Obes Metab. 2011;13:982-9.
11. Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med. 2011;28:333-7.
12. NICE: Liraglutide for the treatment of type 2 diabetes. 2010. http://www.nice.org.uk/nicemedia/live/13248/51259/51259.pdf. Accessed 14 Jun 2012.
13. NICE. The management of type 2 diabetes. Clinical guideline 87. 2009. http://www.nice.org.uk/nicemedia/pdf/CG87NICEGuideline.pdf. Accessed 14 Jun 2012.
14. NICE: Exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes. 2012. http://www.nice.org.uk/nicemedia/live/13670/58205/58205.pdf. Accessed 14 Jun 2012.
15. Buse JB, Rosenstock J, Sesti G, LEAD-6 Study Group, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
16. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia. 2011;54(Suppl. 1):S38. Abstract A75.
17. NICE: Diabetes in adults quality standard. 2011. http://www.nice.org.uk/guidance/qualitystandards/diabetesinadults/diabetesinadultsqualitystandard.jsp. Accessed 14 Jun 2012.
18. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract. 2010;90: 131-40.
19. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetimehealthoutcomesofpatientswith Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747-59.
20. MIMS: http://www.MIMS.co.uk. Accessed 12 Nov 2012.
21. Dibonaventura MD, Wagner JS, Girman CJ, et al. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication. Patient Prefer Adherence. 2010;4:397-406.
22. Davies MJ, Kela R, Khunti K. Liraglutide: overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab. 2011;13:207-20.
23. Buse JB, Sesti G, Schmidt WE, Liraglutide Effect Action in Diabetes-6 Study Group, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-3.
24. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187-94.
25. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90:4888-94.
26. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009;23:463-77.